It’s amazing how months of preparation for a conference are realized in 4-5 intense days. From Sunday afternoon until the wee hours of Thursday morning, BIO-Europe in Berlin was jammed with 40 meetings, good meals, a few great receptions, a Buzz Session, two cigarettes, a few glasses of absinthe refreshment, and a new project or
#BIO2017 is days away. What can we expect? Crowded Partnering – By our unofficial count, the number of companies registered for One-on-One Partnering exceeds the number from San Francisco last year. While having more Exhibitors is nice, more people and companies in Partnering means more opportunities to in- or out-license, find new clients,
An Acceptance Rate is simply the percentage of meeting requests which are accepted at a given conference. At Lacerta Bio, we have been tracking Acceptance Rates for conferences since 2011. We track it for every conference at the corporate level, and also at the client level. But why bother? Daily Planning – Using historical
BIO starts in June, right? Wrong. Perhaps BIO starts in late April, when partnering opens? Sorry. Wrong again. BIO started the moment you decided to include this important conference into your in- or out-licensing plan. For those of you us out-licensing assets, there is at least a 30-60 day
Yeah, it rained last week in San Francisco. But the rain did not stop untold thousands of us from gathering at the many hotels, watering holes, and coffee shops around Union Square. How many of us are present in San Francisco every second week in January? 15,000? 20,000? It’s hard to tell, considering the number
BIO Europe was, yet again, an excellent conference for Lacerta Bio. Having the US election on television screens in the Exhibition Hall made for some surreal moments and discussions. Not a single meeting on Wednesday went without some discussion about the election results. As Americans, we perhaps we do not appreciate how important our elections are
A few weeks ago, we attended the first annual Commercializing Biotech Innovation Conference in Syracuse, New York. The conference was held in the very new Central New York Biotech Accelerator in Syracuse (which is an outstanding facility, by the way). A central theme of the conference (and a subject which was raised several times during the panel discussions) was
Ample numbers of electrons will be spent discussing the BIO2016 conference in San Francisco last week, both positive and negative. Not wanting to be left out of the fun, here are a few of our observations, with the usual caveats about not attending company presentations, etc. Ten Thousand Steps – We averaged 10,274
Next week, our industry makes an unusual return trip to Union Square, as we return for another conference. This time, it’s BIO. BIO is unlike other conferences on our circuit, for a few reasons: Size – BIO isn’t just big. It’s massive. Consider, for example, that there are over 6,000 delegates registered for One-on-One partnering.
How was Bio Europe in Stockholm last week? The Conference Itself – For us, the conference was terrific. We had nearly 30 high-quality meetings over the three days of partnering, plus more informal meetings and catch-ups at the receptions and dinners. As usual, we did not attend any of the company presentations or round-table discussions,
Given that we are now in January, we feel obliged to craft some sort of “Predictions for 2016” post. We’re not big fans of predictive posts, mainly because we’re not very good at it. But more importantly, our industry defies calendar logic, with the rare exception of an FDA panel meeting or similar bimodal event.
This morning, our friends at EBD and MacDougall Biomedical Communications presented a very good webinar on preparing for the upcoming festivities in San Francisco. In case you missed it, I believe the video will be available in the near future. Even if you are an experienced attendee of the January “H&Q” event, the webinar gave
I love what you did with the place… It’s always difficult for us to contribute any sensible overarching overview of any partnering conference, especially BIO Europe Fall. This is entirely our fault, as we’re spending all of our time in partnering meetings and receptions. What the companies have to say is a complete mystery to
Last month, EBD and IMS partnered to analyze meeting outcomes from four conferences, covering nearly 5,000 participating companies. Their report is available here (PDF). As we are knee-deep in scheduling meetings for BIO Europe, we thought it might be interesting to compare their results with ours. To be fair, our experience and success in scheduling
OK, so the new One-on-One Partnering system has not had a stellar introduction. We’re not here to complain about it, as this has been well covered on LinkedIn and elsewhere. But our experience this past month has reminded us of three key lessons which are important in any industry. Customers Rule Let’s make this
Earlier this month, our friends at Biotech and Money published a transcript from a panel discussion at their London 2015 congress. The discussion was quite interesting, and we encourage readers to check it out. The topic for this discussion was whether or not M&A is being brought earlier and earlier into the R&D lifecycle.
We’ve started preparing for the BIO convention in Philadelphia in June. Preparing? Already? Yes. Why start now? We’ll give you three reasons: New Partnering Interface – BIO has unveiled a brand new interface for the One-on-One Partnering system. Everything is new, and the old profiles will NOT automatically populate the new system. You will have
It’s hard to believe that a week has passed since we were dashing from meeting to meeting in San Francisco. We conducted 29 scheduled meetings at the Biotech Showcase, had 15 other scheduled or impromptu meetings elsewhere, attended 4 dinner meetings, 5 receptions, and walked (or ran) 36 kilometers (that’s 22.4 miles if you’re keeping score
The decks have been prepared, edited, and uploaded to the cloud. The meeting schedule is finalized. The objective of each meeting is clear. Air, hotel, and ground transportation is all set. Business cards…comfortable shoes…running gear…all set. Looks like we’re good to go! Here are a few of our thoughts before we end our week and
Can’t get there from here… We’re back from another excellent BIO Europe convention. Held in Frankfurt, this year’s version was attended by over 3,000 industry colleagues, experts, investors, and hangers-on. We spent the bulk of our time in one-on-one partnering meetings and receptions. So we did not attend any of the presentations or the
Lacerta Bio is pleased to return to Europe for the 20th Anniversary of the BIO-Europe conference. We will be there from Sunday evening through Wednesday afternoon. Look for us in PartneringOne, or contact us at email@example.com to schedule a meeting with us. You can also follow the action on Twitter via the #BEU14 hashtag. We’ll also
We’re back and knee-deep in BIO2014 follow up work. Lacerta Bio was joined by 15,665 other “industry leaders” in days full of partnering discussions, pen-grabbing, eating and drinking, and many other sacrifices and challenges that those of us in our industry have to undergo. But, before we forget about our trip, here are a
This morning, Thompson Reuters and BIO presented a good webinar on preparing for BIO. I think it will be re-broadcast tomorrow. A lot of time was spent on characterising transactions on a macro scale, i.e., 2,315 deals in 2013, of which 31% were Licenses and Joint Ventures. While those statistics are interesting, the latter third
We’re still knee-deep in our follow up activities from the San Francisco conferences and receptions. Specifically, we spent the bulk of our time at the rapidly-growing Biotech Showcase at the Parc 55. EBD has summary videos and statistics that will tell you all about the conference. So it’s impossible for us to prepare
We’ve returned from another successful BIO Europe conference, this time in Vienna. We regret not having much time to walk around in Vienna. However, this did not take away from the success of the conference. Here are a few observations as we begin our follow-up process: Attendance Was Up Over 3,000 attendees made their
Lacerta Bio is pleased to announce our participation in the 19th Annual BIO-Europe Conference in Vienna, Austria. As with last year’s conference in Hamburg, this year’s version promises to be an excellent opportunity to meet, partner, and forge new relationships. We are representing several very interesting opportunities in both non-prescription and
As we were making our way back home from Chicago (on delayed flights, of course), several things struck us about BIO2013. We’ve talked about BIO in the past. But how was the ’13 edition different? The same? We spend all of our time in the Business Forum conducting One-on-One meetings. So it is
Now that we’re back from BIO2013, we have to leave again! We’ll be at ExcipientFest 2013 in Baltimore for a few days. We’ll be meeting with several Exhibitors, then meeting with a new client. So if you’ll be in Baltimore early next week, please let us know!
Rob Wright has a really good article on preparing for BIO. In fact, it’s applicable for just about any major conference or convention. You can read the entire article here. His advice is spot on, especially with respect to planning early. He published this article in February, when BIO was “only” 10 weeks
As BD consultants, we attend a number of conferences, both large and small. Some have one-on-one meetings, some don’t. Some are scientific conferences, while others are focused on partnering. As we start preparing for BIO in Chicago, we’d like to share our tips, tricks, and “rules” that we invoke for conferences. Here are a few,
Lacerta Bio, along with approximately 10,000 other life science investors, executives, consultants, service providers, hangers-on, and many others, congregated in San Francisco for a variety of conferences, including the JP Morgan Healthcare Conference, the EBD Biotech Showcase, OneMed Place, and other conferences. We spent the bulk of our time at the “speed dating” meetings at
As we bring 2012 to a close, we’re looking back at a few of the interesting events that took place. It was a challenge to whittle this down to a manageable number. So we decided to go with three. So, without further ado: Pfizer acquires NextWave – This one really surprised a lot of the
Consider the following situation: You are out-licensing an innovative asset in a niche therapeutic area It is a first-in-class molecule It has successfully demonstrated efficacy in two international Phase II clinical trials You complete 20 meetings with prospective national, regional, and international partners at a major business development networking conference You return home and
As we’ve done in the past, we’ve tabulated the countries of origin from the stack of business card collected at BIO Europe 2012. Our “rules” for this analysis are simple. If the person we meet is based in Country A, but reports to headquarters in Country B, then we count that person as coming from
We’ve returned from BIO Europe 2012 in Hamburg with a stack of business cards, pages of meeting notes, prioritized follow ups, and some great memories. We managed to completely fill our calendar with meetings with companies from Europe, Asia, the Middle East, and North America. On behalf of our clients, we are pleased with the
We spent a few days in Chicago attending the AAPS Convention. As usual, it was jammed with excellent science, tons of exhibitors, and great opportunities to catch up with old friends. The Tuesday evening “sessions” were especially enlightening. Here are a few random observations, based on our admittedly limited (2-day) participation: There are a LOT
Next week, Lacerta Bio will be at the AAPS Annual Meeting in Chicago. If you have plans to attend, drop us a note! To follow the action on Twitter, use the hashtag #AAPS2012 Related articles Need international out-licensing help? Lacerta Bio at BIO-Europe 2012 in Hamburg
Lacerta Bio is pleased to announce our attendance at the upcoming BIO-Europe 2012 conference in Hamburg, Germany. In our view, the Fall version of BIO-Europe is the premier partnering conference in Europe. Plus, the good folks at EBD always take good care of us. Look for more details soon here and in the conference
As with BIO 2011, the bulk of our time was spent in the One-on-One Partnering sessions. More general reviews are found here, here, and here. As usual, BIO put on a reasonably good show. Attendance was visibly down from last year, but the enthusiasm remained high in the Partnering area. Anyone with a Phase III
Yesterday, we responded on LinkedIn to the following note: THis is our first BIO conference in June and want to make it a great one. Any hints or helpful suggestions for our booth?. Our response was: Make your booth as self-sustaining as you can, then spend your time on all of the meetings you pre-arranged
Lacerta Bio has returned to cold, windy New York following a solid week in sunny, warm San Francisco. We blogged about last year’s JP Morgan Healthcare conference here . For commentary on what happened inside the Westin, check out posts by Adam Feuerstein , Bruce Booth , and others . Our top highlights were as
Happy New Year, everyone! Next week, 2012 kicks off with the madness otherwise knows as JP Morgan, or #JPM12 if you prefer. We blogged about last year’s conference here. Last year, we were impressed by the optimism, as well as the strong international presence. What can we expect this year? Here are a few “predictions” ahead
We are busy preparing for the Annual Industry kickoff conference at the Westin in San Francisco. Currently, we are scheduling 30-minute meetings on behalf of our clients. Plus, we’re planning our evening reception schedule, which can be a challenge! If you plan on attending, please drop us a line at firstname.lastname@example.org. We are always eager
Lacerta Bio was privileged to give a short talk at the first (and hopefully annual) Drug Delivery Summit in London late last month. While lightly attended, the two-day conference brought several important points to light. First, drug delivery is truly alive and well. Several speakers from multinational pharmaceutical companies illustrated how formulation innovation can be
This week, our good “acquaintances” from EBD Group launched partnering360. What is it? According to EBD: partnering360™ is an online network of professionals in the life science industry, emerging from the global community of 14,000 executives that use EBD Group’s partneringONE® networking software at partnering events held in North America, Europe and Asia. Steve Dickman
Lacerta Bio spent the week at the AAPS ( American Association of Pharmaceutical Scientists ) annual conference . Over 8,000 pharmaceutical scientists, service providers, and others came to AAPS in DC to talk pharmaceutical science, especially formulation development, translational research, pharmacokinetics, and manufacturing. As the name suggests, AAPS is a science-driven conference. Thus, the tone
In a few weeks, Lacerta Bio will return to DC to participate in the annual convention and celebrate the 25th anniversary of the American Association of Pharmaceutical Scientists (AAPS). AAPS is a special organization for us. We and many of our colleagues have been members since our graduate school days. The conferences have always been
Lacerta Bio was fortunate to attend this year’s BioPharm America conference in Boston. Here are a few of our comments and observations: Are Specialty Markets the Future? – Moderated by Bruce Booth, the panel discussed the shift from primary care to specialty markets by Big Pharma/Big Biotech. A few interesting notes: Price cuts, even in
Posts have been light lately, due to vacations, summer hours, etc. However, we’ve remained busy with client work and keeping up with the news. A few recent news items of interest: What Hollywood can teach us about drug development: Forbes’ Matthew Herper published a terrific article on what’s broken with the pharma product development model.
We previously posted our comments on BIO 2011. However, one aspect of the conference that really stood out was the use of social media. Attendees were encouraged to provide links to our LinkedIn, FaceBook, Twitter, and other accounts for the myBio web site. The velocity of tweets from the convention was astounding (and continues). And,
The Lacerta Bio team attended the annual BIO Convention in Washington, DC last week. BIO has become one of the key conventions for pharma/biotech business development, and is a “must attend” event for many of us in business development. Our observations are somewhat limited, as we spent the bulk of our time in one-on-one partnering
We regret that we were unable to attend the panel discussions at BioTrinity last week. However, an excellent summary was posted on the PharmaPhorum web site. Of note: 1. Investment syndication is becoming increasingly important. 2. Big pharma/Big biotech are looking at earlier-stage assets, perhaps more so than ever. Even early-stage technologies coming out of
Last week, Lacerta Bio attended the annual BioTrinity Partnering and Investment Conference in Newbury, UK. This was our first time at this conference. So how was the conference? A few observations: 1. We had no trouble scheduling and conducting high-quality meetings on behalf of our clients. Our calendars were completely filled on both partnering days.
This weekend was spent attending the Natural Products ExpoWest convention in Anaheim on behalf of a few of our clients. This was our first time attending this conference. Aside from the great food in Hallway E, we spent our time representing our clients and learning a lot. Our impressions: 1. There is an increasing demand for
There is a lot of good commentary and analysis of last week’s JP Morgan Healthcare conference, most notably here, here, and here. Here are a few of our thoughts as we look back at the conference: 1. Maybe it’s because it’s the start of a new year, or perhaps it’s that we’ve come out of
In our meetings and informal discussions, there were three items we heard again and again: 1. Last year was a terrible fund raising year from a VC-backed company perspective. 2. This year will be much better. Indeed, there is a palpable sense of optimism that more companies will receive more funding in 2011, but… 3.
Like many of you, we are already scheduling meetings at the annual JP Morgan Healthcare Conference in San Francisco in January. This is an invitation-only event, but that doesn’t stop hundreds of us from meeting and kicking off 2011. While JP Morgan does not list the conference on their website, LinkedIn does as a virtual